USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ENANTIGEN THERAPEUTICS, INC.
City: DOYLESTOWN
State: PA
Zip+4: 18902-8400
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: http://enantigen.com
Phone: (215) 589-6350

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,177,154.00 4
STTR Phase I $99,967.00 1
STTR Phase II $738,292.00 1

Award List:

Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency / Branch: DOD / DARPA
Research Institution: New York University
Principal Investigator: Neville R. Kallenbach, Professor of Chemistry
Award Amount: $99,967.00
RI Contact: Eric Bybee
Abstract:
This project addresses two pressing problems in treating bacterial infections: the emerging resistance against current antibiotics and the role of biofilm formation in these infections. Based ona successful lead dendrimerthat acts against a broad spectrum of MDR pathogens including A.baumannii, and… More

Development of a Therapy for Dengue Virus Infection

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Xiaodong Xu
Award Amount: $282,480.00
Abstract:
DESCRIPTION (provided by applicant): This is a Phase I proposal to develop a new family of imino sugars, with break through , unprecedented, potency, for the treatment of dengue virus (DENV) infection. There is currently no effective treatment for disease s caused by this virus and both the public… More

Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms

Award Year / Program / Phase: 2012 / STTR / Phase II
Agency / Branch: DOD / ARMY
Research Institution: New York University
Principal Investigator: Xiaodong X. PhD, President – (215) 589-6350
Award Amount: $738,292.00
RI Contact: Richard Louth
Abstract:
This project builds on patterns derived from natural antimicrobial peptide sequences to develop novel compounds with better systemic activity, lower cytotoxicity and broader spectrum activity against multidrug resistant (MDR) pathogens. In Phase I and the

Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV Inf

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Xiaodong Xu – 215-589-6350
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): This is a proposal to develop newly discovered sulfamoylbenzamide derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, a… More

Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents aga

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Xiaodong Xu – 215-589-6350
Award Amount: $294,674.00
Abstract:
DESCRIPTION (provided by applicant): This is a phase I proposal to determine the feasibility of developing newly discovered fluorinated sulfamoylbenzamide (FSBA) derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as… More

Neural Probe for high spatial and temporal resolution detection of cocaine and su

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrea Cuconati – 215-489-4918
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): This is a proposal to implement a novel high throughput assay system to detect inhibitors of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) formation and/or maintenance. HBV cccDNA is essential to the virus life cycle and its elimination during… More